ASCO’s Annual Meeting will feature GIST in 18 abstracts, posters, panels, and presentations. Here is a preview of the topics that will be presented at the conference in June. We will be reviewing these items during and after the conference. 2022’s conference theme is Advancing Equitable Cancer Care Through Innovation. #ASCO22
ASCO 2022 ABSTRACTS & PRESENTATIONS
2022 ASCO Annual Meeting – Poster Session:
Second primary malignancies (SPM) in patients with gastrointestinal stromal tumors (GIST):
10-year experience from the Ottawa Hospital (TOH). First Author: Abdulhameed Alfagih MD
2022 ASCO Annual Meeting – Education Session
Panel Question & Answer
2022 ASCO Annual Meeting – Publication Only
The long-term analysis of prognostic role of mutational status in primary resectable gastrointestinal stromal tumors (GIST).
First Author: Pawel Sobczuk MD
2022 ASCO Annual Meeting – Poster Session
Selective internal radioembolization (SIRT) allows to control liver metastases of gastrointestinal stromal tumors (GIST) failing treatment with tyrosine kinase inhibitors (TKI). First Author: Peter Hohenberger PhD, MD
2022 ASCO Annual Meeting – Poster Discussion Session
Should Mutation Status Drive Treatment Selection in Gastrointestinal Stromal Tumor?
Discussant: Jason K. Sicklick MD
2022 ASCO Annual Meeting – Poster Discussion Session
Promising antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor- (TKI-) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST). First Author: Haibo Qiu
2022 ASCO Annual Meeting – Clinical Science Symposium
Circulating tumor DNA (ctDNA) analyses of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor (GIST). First Author: Cesar Serrano PhD, MD
2022 ASCO Annual Meeting – Poster Session
Platelet derived growth factor receptor alpha (PDGFRA) mutant gastrointestinal stromal tumours (GISTs): Clinicopathological characteristics and outcomes from a regional centre in the United Kingdom. First Author: David M Favara MD, D.Phil
2022 ASCO Annual Meeting – Poster Session
Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions. First Author: Yoon-Koo Kang PhD, MD
2022 ASCO Annual Meeting – Poster Discussion Session
A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST). First Author: Suzanne George MD
2022 ASCO Annual Meeting – Poster Session
Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor who are in complete radiological remission: A prospective multicenter phase II study.
First Author: Ivar Hompland
2022 ASCO Annual Meeting – Poster Session
A randomized phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors.
First Author: Hyung-Don Kim
2022 ASCO Annual Meeting – Poster Discussion Session
KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor.
First Author: Steven Bialick DO
2022 ASCO Annual Meeting – Education Session
Update on the Role of Ancillary Pathologic Techniques in Optimizing Targeted Therapy for Gastrointestinal Stromal Tumors.
Speaker: Inga-Marie Schaefer MD
2022 ASCO Annual Meeting – Education Session
Updates on Abstract 359881: INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib.
Speaker: Michael C. Heinrich FACP, MD
2022 ASCO Annual Meeting – Publication Only
Outcome and surveillance pattern in older GIST population. First Author: Thanh P. Ho MD
2022 ASCO Annual Meeting – Education Session
Novel Tyrosine Kinase Inhibitors for the Management of Locally Advanced and Metastatic Gastrointestinal Stromal Tumors.
Chair: Cesar Serrano PhD, MD
2022 ASCO Annual Meeting – Education Session
Shifting Indications for Surgery in Management of Locally Advanced and Metastatic Gastrointestinal Stromal Tumor.
Speaker: Ronald P. DeMatteo MD, FACS
